
What does -prazole mean?
The -prazole stem marks a proton pump inhibitor. Why irreversible binding makes the effect outlast the drug, why dosing is before food, and the CYP2C19 trap.

Short answer: A drug ending in -terol is a beta-2 adrenoceptor agonist, used almost entirely to relax bronchial smooth muscle. Every side effect the class has is that same receptor being stimulated somewhere it was not wanted, which is why tremor and a falling potassium are expected rather than surprising.
Generic drug names are not invented freely. The USAN Council assigns stems so that related compounds share a family name, stating plainly that the purpose is to make prescribing safer by giving immediate recognition. The WHO INN Stem Book does the same job internationally. The stem sits inside the broader adrenergic naming convention and marks selectivity for the beta-2 subtype specifically. That selectivity is relative rather than absolute, and the doses used in an acute attack are high enough that beta-1 effects appear, which is the single most useful caveat to carry.
Beta receptors divide by tissue. Beta-1 predominates in the heart, where stimulation raises rate and force. Beta-2 sits on bronchial smooth muscle, on vessels supplying skeletal muscle, in the liver and in skeletal muscle itself, and stimulation there relaxes smooth muscle. Targeting beta-2 therefore opens the airway while leaving the heart comparatively alone, which is exactly the separation an inhaled reliever needs.
Skeletal muscle carries beta-2 receptors, and stimulating them produces a fine tremor. This is the intended drug acting at the intended receptor in an unintended tissue, which is a different thing from toxicity. It tends to settle with continued use as tolerance develops at that site, and it is most obvious after high-dose nebulised treatment where systemic absorption is greatest.
Beta-2 stimulation activates the sodium-potassium ATPase, which pumps potassium from the extracellular space into cells. Plasma potassium therefore drops while total body potassium is unchanged. This matters after repeated nebulised doses in an acute attack, particularly alongside a corticosteroid or a diuretic, and it is a favourite exam scenario precisely because nothing has actually been excreted.
Salmeterol carries a long lipophilic tail that embeds in the cell membrane beside the receptor, so the active part of the molecule keeps re-engaging instead of diffusing away. That anchoring produces around twelve hours of action. It also means the drug must partition into the membrane before it works, which makes the onset slow and makes it useless for rescue. Formoterol is the exception, being both long acting and fast in onset.
Asthma is an inflammatory disease and a bronchodilator treats only the symptom. Using a long-acting beta-2 agonist without an inhaled corticosteroid can leave the patient feeling controlled while the underlying inflammation worsens, and trials found excess asthma deaths with that pattern of use. This is why combination inhalers exist and why monotherapy is contraindicated rather than merely discouraged.
Every fact in this topic has a matching fact in the beta blocker topic. A non-selective beta blocker causes bronchospasm because it blocks the beta-2 receptors a -terol drug is trying to stimulate. Beta blockade masks hypoglycaemia because the warning symptoms are beta-mediated, and beta-2 stimulation shifts potassium the opposite way to beta blockade. Learning one class gives you most of the other for free.
The members differ on onset and duration rather than on receptor, and that difference decides whether a drug is a reliever or a preventer.
| Drug | Onset and duration | Role |
|---|---|---|
| Salbutamol | Minutes, 4 to 6 hours | Reliever |
| Terbutaline | Minutes, short acting | Reliever |
| Salmeterol | Slow, about 12 hours | Preventer, with a steroid |
| Formoterol | Fast, about 12 hours | Preventer, and usable as reliever in some regimens |
| Vilanterol | Fast, 24 hours | Once-daily combination inhalers |
The ending identifies the receptor but not the duration, and duration is the property that decides clinical role. Salbutamol and salmeterol share a stem and could not be more different in an emergency. This is the clearest case in the naming system where the stem gets you to the class and then stops, and the remaining distinction has to be learned per drug.
An unfamiliar -terol tells you it is a bronchodilator, that tremor and a low potassium are expected effects rather than adverse events, that it should not appear alone in an asthma regimen if it is long acting, and that a patient on a non-selective beta blocker will get less benefit from it. A question combining an asthmatic with propranolol is testing whether you can see the two classes cancelling.
Delivering the drug straight to bronchial smooth muscle achieves a high local concentration from a very small dose, which keeps systemic exposure low and therefore keeps tremor and tachycardia to a minimum. The trade is that inhaler technique becomes part of the pharmacology: a poorly coordinated actuation deposits most of the dose in the mouth, where it does nothing useful. Checking technique is often more productive than escalating the dose.
Continuous beta-2 stimulation downregulates the receptor, so frequent scheduled use of a short-acting agent can blunt the response over time. This is one reason a rising reliever count is treated as a marker of poor control rather than simply as a supply problem. Corticosteroids upregulate beta receptors, which is part of why inhaled steroid treatment restores bronchodilator responsiveness as well as reducing inflammation.
The potassium shift that appears as a side effect in asthma treatment is exploited as a therapy in hyperkalaemia, where nebulised salbutamol drives potassium into cells alongside insulin and glucose. Nothing is removed from the body by either, so both are holding measures while a route of actual elimination is arranged. Recognising that one drug effect is a side effect in one context and the treatment in another is a useful habit.
Uterine smooth muscle carries beta-2 receptors, and terbutaline has been used to relax the uterus in preterm labour and in uterine hyperstimulation, though prolonged use for tocolysis is now restricted because of maternal cardiac effects. Skeletal muscle, hepatic glycogenolysis and vessels supplying muscle all respond too. The stem points at a receptor rather than an organ, and the receptor is distributed more widely than the indication suggests.
The pairing that matters most is salbutamol versus salmeterol, because the same receptor produces a reliever and a preventer. The beta blocker post covers the mirror image, the autonomic receptor map places beta-2 alongside every other adrenergic receptor, and the autonomic practice set will test whether the map has stuck.
The method below works for any generic name, which is the point of learning naming as a system rather than learning drugs one at a time. Start at the end of the word, because that is where the stem almost always sits, and read backwards until you reach something familiar. Endings are assigned; beginnings are usually the manufacturer distinguishing one compound from its siblings, so the front of the name carries far less information.
Next, ask what the stem predicts. A good stem gives you a target or a chemical family, and from either you can usually derive the main effect and the principal side effect, because most adverse effects are the intended action appearing in a tissue where it was not wanted. Then look deliberately for the exception, since every stem has one and exams are built on exactly those cases.
Finally, check rather than assume. A stem narrows the possibilities; it does not replace the label. Drugs that share a target can carry different stems if their chemistry differs, and drugs that share a stem can differ enormously in duration, which is frequently the property that decides how each is used. Treat the ending as a strong hypothesis that gets you most of the way to an answer, then confirm the detail against a primary source before it matters clinically.
It marks a beta-2 adrenoceptor agonist, used mainly to relax bronchial smooth muscle. Selectivity for beta-2 is relative rather than absolute, so beta-1 effects appear at the high doses used in acute treatment.
Skeletal muscle carries beta-2 receptors, so stimulating them produces a fine tremor. It is the intended drug at the intended receptor in an unintended tissue, and it usually settles with continued use.
Beta-2 stimulation activates the sodium-potassium ATPase, driving potassium into cells. Plasma potassium falls while total body potassium is unchanged, so nothing has actually been lost.
It relieves bronchoconstriction without treating the underlying inflammation, which can mask deterioration. Trials found excess asthma deaths with monotherapy, so it is combined with an inhaled corticosteroid.
Formoterol has a fast onset despite lasting around twelve hours, which is why some regimens use it as both preventer and reliever. Salmeterol is slow in onset and cannot be used for rescue.
This stem is worth learning twice over, because it comes with a free second class. Every fact about beta-2 stimulation has a mirror in beta blockade, so the effort spent understanding why salbutamol causes tremor also explains why propranolol causes bronchospasm and why it hides a hypoglycaemic episode. Two classes, one receptor family, and the naming system pointing at both.
For study only. This article is written for learning and examination practice. It is not medical advice, not clinical decision support, and must never be used to make a decision about a real patient. Always verify against your local formulary, the product literature and a qualified pharmacist.
One mechanism explained properly every day, then brought back before you forget it.
Free to download. 7-day Pro trial. No credit card.